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Abstract During the last two decades a large number of
genetically modified mouse lines with altered gonadotropin
action have been generated. These mouse lines fall into three
categories: the lack-of-function mice, gain-of-function mice,
and the mice generated by breeding the abovementioned lines
with other disease model lines. The mouse strains lacking
gonadotropin action have elucidated the necessity of the
pituitary hormones in pubertal development and function of
gonads, and revealed the processes from the original genetic
defect to the pathological phenotype such as hypo- or hyper-
gonadotropic hypogonadism. Conversely, the strains of the
second group depict consequences of chronic gonadotropin
action. The lines vary from those expressing constitutively
active receptors and those secreting follicle-stimulating hor-
mone (FSH) with slowly increasing amounts to those
producing human choriogonadotropin (hCG), amount of which
corresponds to 2000-fold luteinizing hormone (LH)/hCG
biological activity. Accordingly, the phenotypes diverge from
mild anomalies and enhanced fertility to disrupted gametogen-
esis, but eventually chronic, enhanced and non-pulsatile action
of both FSH and LH leads to female and male infertility and/or
hyper- and neoplasias in most of the gonadotropin gain-of-
function mice. Elevated gonadotropin levels also alter the
function of several extra-gonadal tissues either directly or
indirectly via increased sex steroid production. These effects
include promotion of tumorigenesis in tissues such as the
pituitary, mammary and adrenal glands. Finally, the cross-
breedings of the current mouse strains with other disease
models are likely to uncover the contribution of gonadotropins
in novel biological systems, as exemplified by the recent
crossbreed of LHCG receptor deficient mice with Alzheimer
disease mice.
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1 Introduction
Since the close connection between pituitary and gonads
was revealed, luteinizing hormone (LH), follicle-
stimulating hormone (FSH) and their receptors have been
intensively studied with the aim of understanding the
function and malfunction of these organs. In this current
review we concentrate on the experimental animal models
that have elucidated the role of gonadotropins in normal
gonadal function and, more importantly, what aberrations
are caused by their abnormal actions in gonads and extra-
gonadal tissues. Numerous mouse models with disrupted or
enhanced gonadotropin signalling have been generated
(Table 1). The phenotypes of these mice mimic several
human conditions such as hypo- or hypergonadotropin
hypogonadism, premature ovarian failure and ovarian
hyperstimulation syndrome. The mouse strains and their
crosses with other disease model lines are also useful when
testing other hypotheses, such as gonadotropin action in
tumorigenesis, bone metabolism and Alzheimer disease.
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2 Experimental animal models for gonadotropin action
in ovary
The main target of gonadotropins in females is the ovary,
maturation of which is triggered by LH and FSH at puberty.
It is largely agreed and confirmed by animal models lacking
FSH, LH or their receptors that the gonadotropins are not
critical for the prenatal female uro-genital development.
Nevertheless, loss-of-function mutations in any of the
gonadotropins or their receptors lead to delayed or
interrupted progression of puberty, hypogonadism, primary
amenorrhea, and consequently infertility [1–6]. In the
absence of FSH or LH signalling, ovarian follicle growth
does not progress beyond the preantral or early antral stage,
respectively, leading to a deficit in estrogen and progester-
one production and anovulation both in humans and
Table 1 Mouse lines with disrupted or enhanced gonadotropin production and loss- and gain-of-function mutations of gonadotropins and their
receptor
A. Mouse lines with disrupted gonadotropin productiona
Mouse line Gene modification References
Kiss1−/− Deletion of the exons 1 and 2 [79]
Gpr54−/− Disruption of the first and second exon; disruption of the second exon [80, 81]
hpg Spontaneous mutation; deletion of the exons 3 and 4 of Gnrh [82]
GnrhrL117P ENU-induced mutation [83]
Gnrhr−/− Gene trap insertion to disrupt the exons 2 and 3 [84]
B. Mouse lines with loss-of-function modification in a gonadotropin or its receptor
hpg Spontaneous mutation; deletion of the exons 3 and 4 of Gnrh [82]
Fshβ−/− Deletion of the exons 1-3 [1]
Fshr−/−, Forko Deletion of the exon 1 [2, 3]
Lhβ−/− Disruption of the second exon [4]
Lhcgr−/−, Lurko Deletion of the exon 11; deletion of the exon1 [5, 6]
C. Mouse lines with enhanced gonadotropin action
Mouse line Promoter(s) Gene modification References
LhβCTP+ bCGA Transgenic line expressing the fusion gene of bLHB and CGB [31]
LhβCTP+xTag bCGA and Inha Double transgenic line expressing the fusion gene of bLHB and CGB and SV40 Tag [38]
UBC-hCGβ+b UBC Transgenic line expressing CGB [33]
Mt1-hCGβ+b Mt1 Transgenic line expressing CGB [30]
UBC-hCG+b UBC Double transgenic line expressing CGA and CGB [44]
Mt1-hCG+b Mt1 Double transgenic line expressing CGA and CGB [30]
YHR+ Inha Transgenic line expressing the fusion gene of CGA, CGB and rLhcgr [32]
rLHRD556+ Inha Transgenic line expressing CAM rLhcgr D556 [32]
Mt1-hFSH+b Mt1 Double transgenic line expressing CGA and FSHB [24]
Ins2-hFSH+b rIns2 Double transgenic line expressing CGA and FSHB [22]
Ins2-hFSH+xhpg rIns2 Ins2-hFSH+ in hpg background [85]
FSHRD567G+xhpg rAbp Transgenic line expressing CAM FSHRD567G in hpg background [86, 87]
FSHR+xhpg rAbp Transgenic line expressing FSHR in hpg background [87]
FshrD580Y+ AMH Transgenic line expressing CAM FshrD580Y [18]
FshrD580H+ AMH Transgenic line expressing CAM FshrD580H [18]
FshrD580Y-ki endogenous Fshr Knock-in line expressing CAM FshrD580Y [18]
ENU N-ethyl-N-nitrosurea
b bovine; h human; m mouse; r rat; ABP androgen binding protein; AMH anti-Mullerian hormone; CGA glycoprotein hormone—alpha
polypepitide (α-subunit); CGB beta; FSHB follicle stimulating hormone beta; Fshr follicle stimulating hormone; Gnrhr gonadotroping releasing
hormone receptor; Gpr G protein-coupled receptor; hpg hypogonadal; Ins insulin; Kiss kiss-metastasis suppressor; LHB luteinizing hormone beta;
Lhcgr luteinizing hormone/choriogonadotropin hormone receptor; Mt metallothionein; SV40 Simian virus 40; Tag T-antigen; UB ubiquitin; CAM
constitutively active mutant
+ Depicts expression of a transgene in addition to endogenous genes
a The focus of the review being in the aberrations of gonadotropin action, the mice of the section A have been listed to demonstrate upstream
events of the gonadotropin biosynthesis, but they have not been discussed except hpg mice
bWhen two different mouse strains expressing the same gene but under different promoter have been generated, abbreviation of a promoter has
been included into the strain name
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rodents. Mice lacking gonadotropin function and their
consistency with corresponding human ovarian conditions
have been discussed in detail in several excellent review
articles elsewhere [7–10]. Therefore we concentrate here in
more detail on the role of gonadotropins in folliculogenesis,
ovarian tumorigenesis and on the consequences of excess
gonadotropin signalling, as demonstrated by the genetically
manipulated animal models.
2.1 Role of gonadotropins in the formation
and maintenance of the primordial follicle pool
The gonadotropin-dependence of ovarian function begins at
puberty and involves the advanced follicular stages, but
gonadotropins—and FSH in particular—may also affect the
earlier stages starting the neonatal primordial folliculo-
genesis. FSH receptor (Fshr) is expressed in the neonatal
mouse ovary and its expression increases significantly
within the first three postnatal days together with serum
FSH. In vitro FSH promotes mouse oocyte survival during
the initial follicle formation by decreasing the apoptosis of
the oocytes and by timing germline nest breakdown [11].
Similarly, the serum FSH peak coincides with the time of
nest breakdown in developing human ovaries [12]. The
early involvement of FSH in initial folliculogenesis is
further emphasised by the data showing that anti-FSH
treatment of hamster dams during pregnancy leads to
reduced number of primordial follicles in pups [13] and
that the amount of naked oocytes is substantially reduced in
2-day-old FSHR-deficient Forko mice. [14]. In addition,
there are more growing, i.e. primary and secondary follicles
in the newborn Forko mice than in wild-type animals,
indicating disturbances in the timing of the initial follicular
recruitment in the absence of FSH signalling.
In pubertal Forko females, the loss of primordial follicles
is not accelerated compared to wild-type mice, suggesting
that FSH action is not needed to maintain the primordial
follicle pool. Conversely, FSH signalling linked to anti-
Műllerian hormone (AMH) action may be involved in
removing the excess of primordial follicles after the initial
formation of the pool [14, 15]. In pubertal Forko [14] and
adult hypogonadal (hpg) [16] mice that are lacking both LH
and FSH, the number of primordial follicles is higher than
in age-matched wild-type mice, and gonadotropin treatment
of the hpg females causes an accelerated decrease of the
follicular pool. In agreement, chronically elevated LH [17]
and the constitutively active form of mFSHR, mFSHR-
D580H [18], lead to substantially accelerated loss of
primordial follicles in the adult mice. Atresia of primordial
follicles is apparently increased in the presence of excess
gonadotropin action, since their augmented recruitment into
the growing pool has not been detected [17, 18]. Since the
gonadotropin receptors are absent in primordial follicles
[19–21], the larger gonadotropin-responsive follicles may
secrete a factor/factors promoting apoptosis of primordial
follicles or inactivate any other/s supporting their survival.
2.2 Aberrant gonadotropin action during the gonadotropin-
responsive, but not -dependent phase of follicular growth
in mature mice
During follicular growth the earliest signs of FSHR and
Fshr expression have been detected in the cuboidal
granulosa cells of the primary follicles with a subsequent
increase in more advanced follicles [19, 20]. The expres-
sion of ligand-responsive luteinizing/choriogonadotropin
receptor (LHCGR) begins in the forming theca cell layer
[21]. During this gonadotropin-responsive, but not yet
dependent phase, the lack of gonadotropin signalling results
in decreased number of secondary follicles [14, 16], but
more importantly, they are susceptible to the excess of
gonadotropin action, for instance caused by gain-of-
function mutations in their receptors or exogenous gonad-
otropin production by endocrine tumors. Both chronically
elevated LH [17] and FSH [22] as well as action of the
constitutively active FSHR-D580H [18] lead to accelerated
loss of small growing follicles and to abnormalities in the
remaining follicles. The low number of the small growing
follicles may thus be caused by the earlier described
exhaustion of the resting follicle reserve and consequently
decreased number of the recruited follicles. The enhanced
gonadotropin action can also accelerate the growth of the
remaining recruited follicles as it happens in mice express-
ing FSHR-D580H, FshrD580H+ mice [18].
The collective data from the animal models suggest that
during the early steps of folliculogenesis FSH is involved in
the timing of the germline nest breakdown, protecting the
perinatal primordial pool, and initiating the follicle recruit-
ment (Table 2). Later on the protective role of FSH for the
primordial pool is lost and conversely, the excess of FSH
and LH indirectly accelerates the loss of primordial
follicles. Both absent and increased FSH and LH action
results in a reduced number of small growing follicles, and
the augmented gonadotropin action leads to defects in the
remaining follicles (see below). Therefore unbalanced
gonadotropin signalling may be a factor leading to
premature ovarian failure in women.
2.3 Aberrant gonadotropin action during the gonadotropin-
dependent phase of follicular growth
In the absence of FSH and LH action, ovarian follicles
develop until the preantral and early antral stage, respec-
tively [1–6] (Table 2), thus verifying the need for
gonadotropins in cyclic recruitment and pre-ovulatory
growth of follicles, but not for the initial formation of
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granulosa or thecal cell layers. Arrest of follicle develop-
ment results in small ovarian size, decreased production of
inhibins [3] and estradiol [4–6, 23] as well as missing
ovulation and luteinisation, leading to decreased progester-
one production [1, 4, 6, 23]. The insufficient production of
ovarian hormones causes uterine atrophy and disordered
estrous cycles, and the concomitant lack of negative
feedback from ovary to hypothalamic-pituitary axis results
in chronic secretion of both FSH and LH, when either of
the gonadotropin receptor is missing [1–6]. Increased and
non-pulsatile secretion of one gonadotropin, however,
cannot compensate for the lack of the other.
Chronically increased FSH action causes serious abnor-
malities in ovarian function that correlates to the level of
the excess of FSH signalling. The Ins2-hFSH+ line
represents the situation, in which the serum concentration
of FSH gradually rises during the aging of the mice. The
augmented FSH levels in Ins2-hFSH+ mice exert a
biphasic effect on fecundity, first seen as increased litter
size but later as premature infertility [22]. Similarly, young
FshrD580H+ mice expressing a modest level of constitu-
tively active receptor show increased fertility, but with
aging or upon further increased expression of FshrD580H
their fertility is severely compromised [18]. Expression of
Cyp19 is increased in the FshrD580H+ ovaries causing
increased estradiol production and consequently high
prolactin secretion. These apparent changes cause pertur-
bation of the LH surge leading to appearance of
luteinized—but unruptured follicles (Fig. 1a–b). In
addition, the hormonal imbalance disrupts the estrous
cycle, and alters the vaginal epithelium and its capacity to
support implantation. Also other structural alterations are
common in the FshrD580H+ ovaries; at the age of 2 to
3 months they are hyperstimulated, but contain numerous
hemorrhagic follicles of poor quality (Fig. 1a–b); periodic
acid Schiff—positive cell clusters with foamy and multi-
nuclear cells are evident in ageing mice (Fig. 1c–f); and in
the most affected animals the surface epithelium is
hyperplastic [18]. In addition, germ-cell tumors, terato-
mas, are apparent in a fraction of the FshrD580H+ ovaries
[18]. Finally, the supra-physiological amount of circulat-
ing FSH in Mt1-FSH+ mice leads to quick deterioration of
follicle function and infertility [24]. Folliculogenesis
initiates normally in these mice, but by 6–7 weeks of
age the ovaries are packed with massive fluid-filled and
hemorrhagic cysts, and in 8-month old mice no late-stage
follicles or corpora lutea are seen any more [24].
FSH acts as a determining factor in the cyclic recruitment of
follicles and as a survival factor for antral follicles to rescue
them from atresia [25]. The current mouse strains show that
excess FSH action can also overrule quantity and quality
control mechanisms in selection of dominant follicles such as
those regulated by AMH [26]. FSH regulates the proliferation
of granulosa cells in the growing follicles, which function is
reflected by decreased cyclin D2 expression in Forko mice
[14] and increased Ki67 expression in FshrD580H+ mice [18].
A notably higher number of primary and secondary follicles
are Ki67-positive in FshrD580H+ than in wild-type mice, thus
apparently leading to the accelerated growth of the follicles
and explaining the ovarian hyperstimulation detected in
young adult FshrD580H+ females (Fig. 1a–b). These mice
have an increased number of large growing follicles, several
of them being hemorrhagic, and the progression into large
follicles continues even though the ovaries show premature
ageing and accelerated loss of small follicles (Fig. 1c–e) [18].
In agreement, the amount of corpora lutea and uterine
implantation are significantly higher in young Ins2-hFSH+
than wild-type females leading to larger litters [22]. When
Table 2 Influence of the aberrant gonadotropin action on the folliculogenesis. In each case the condition has been compared with the situation in
a wild type mouse
Loss of FSH
action
Increased FSH
action
Loss of LH
action
Increased LH/hCG
action
References
Postnatal mouse
Amount of naked oocytes; initial
primordial folliculogenesis
Decreased Increased dna dna [11, 14]
The initial recruitment Increased dna dna dna [14]
Peripubertal and adult mouse
The pool of primordial follicles Larger Decreased Larger Decreased [14, 16–18]
Number of small follicles
(primary to preantral)
Decreased Decreased dna Decreased [14, 16–18]
Number of antral follicles No antral follicles Increased in young
mature animals
Only early antral follicles No effect [1–6, 17, 18]
Presence of hemorrhagic follicles Not reported Yes Not reported Yes [18, 24, 30–32]
dna data not available
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Ins2-hFSH+ females become older their litter sizes decrease
due to increased reabsorption of embryos, also implying poor
quality of ovulated and fertilized oocytes. It is generally
understood that the leading follicles grow faster than the rest
of the cohort producing higher amounts of estradiol and
inhibins than the others [25]. Ins2-hFSH+ and FshrD580H+
females, however, escape the negative feedback of estrogens
and inhibins and its influence on FSH secretion, and thus also
the remaining antral follicles besides the leading ones
continue to grow, bringing about the phenotype of hyper-
stimulated ovaries. It mimics the ethiology of the human
pregnancy-dependent ovarian hyperstimulation syndrome that
is caused by activation of a mutated ligand-nonspecific FSHR
by hCG [27].
While FSH signalling is critical for the follicular
development from preantral to early antral phase, LH
signalling is essential for the further steps to pre-ovulatory
stage and ovulation, and it cannot be compensated for by
high-dose FSH [28]. The under-development of the
reproductive organs and female infertility are due to low
estrogen production and anovulation in Lhcgr deficient
Lurko mice. Accordingly they demonstrate a dramatic
decrease in the ovarian mRNAs for steroidogenic proteins,
steroidogenic acute regulatory protein (StAR), cytochrome
P450-side-chain cleavage (P450-scc), and P450-aromatase
with being practically undetectable [6, 28]. Lurko mice also
lack the LH stimulus that is needed to express sufficiently
and temporally several genes associated with ovulation,
such as Pr, Cox-2, Tsg-6, amphiregulin, epiregulin and β-
cellulin [28]. Whereas high doses of FSH can induce
ovulation in hypophysectomised rodents [29], this does not
occur in Lurko mice indicating that Lhcgr expression, by
unknown mechanism, may be needed for the FSH-induced
ovulation. Whether LHCGR/FSHR dimerisation is neces-
sary for this event remains to be evaluated.
Excessive LH signalling also leads to female infertility
due to abnormal follicle maturation and lack of ovulation.
Depending on amount of excessive gonadotropin stimula-
tion, transgenic female mice develop progressively failing
ovaries. The young low-copy Mt1-hCG+ females produce
offspring similar to wild-type mice, but the former become
infertile by 6–7 months for unknown reasons [30].
Folliculogenesis in high-copy Mt1-hCG+ females, instead,
disrupts before ovulation and the ovaries turn largely
hemorrhagic and cystic, the mice thus being infertile
through their life. In young LhβCTP+ [31], YHR+ [32],
and UBC-hCGβ+ [33] mice (for details see Table 1),
folliculogenesis progresses until luteinization, but due to
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UBC-hCG + 3 mo 
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Fig. 1 An example of ovaries
affected by chronically elevated
gonadotropin action. Micro-
graphs of ovarian sections from
wild-type (wt) mice (a, c), mice
expressing constitutively active
FSHR (FshrD580H+) (b, d–e) and
mice expressing hCGβ-subunit
(UBC-hCGβ+) (f). Arrowheads
indicate oocytes trapped inside
lutenized follicles in the hyper-
stimulated FshrD580H+ ovary (b);
arrows indicate multinuclear and
foamy cell clusters in the ovaries
of ageing FshrD580H+ mice (d,
e). UBC-hCGβ+females have
heavily luteinized ovaries (aster-
isk) by the age of 3 months (f).
AF antral follicle; SF second-
ary follicle; H haemorrhage;
CL corpus luteum; mo month.
Scale bar 500 μm
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constant LH/hCG stimulus rather than a gonadotropin
surge, oocytes are found trapped inside luteinized follicles
and mice are infertile. At the age of 1 month estradiol
production is increased in UBC-hCGβ+ mice [33], but as
the females ages, intensive luteinization takes place
(Fig. 1f), and the elevated estradiol concentration is
replaced by high progesterone and testosterone secretion
[33]. In LhβCTP+ [31] and YHR+ [32] females estradiol
production remains elevated aside increased progesterone
production, leading to hypertrophic uterine growth. More-
over, very high hCG production—comparable to 2000-fold
biological LH/CG activity—in UBC-hCG+ females causes
formation of bilateral teratomas.
In LHβCTP and YHR+ strains LH signalling is
prematurely initiated, and evident precocious puberty
occurs in female mice reflected by early vaginal opening,
advanced follicle growth and an enlarged uterus [32, 34].
The results imply that prepubertally excessive LH action
is able to trigger increased estradiol production despite
reduced FSH concentration. While the different
gonadotropin-related mouse models in general are good
phenocopies for several human disorders, in case of
gonadotropin-related precocious puberty there are distinct
dissimilarities between the species. Women carrying the
same gain-of-mutations in LHCGR that causes testotox-
icosis in their male relatives do not suffer from any
obvious endocrine problems such as premature puberty,
hyperandrogenism or infertility, contrasting the LHβCTP
and YHR+ females. Both quantitative and qualitative
dissimilarities in hormone action may explain the differ-
ences between the species; excessive LH signalling in
LHβCTP and YHR+ females may be more robust than that
in women carrying constitutively active LHCGR, and it is
thus able to reach the threshold needed for the initiation of
puberty. Moreover constitutively active forms of human
LHCGR can be further stimulated by LH to trigger an LH
surge effect and enable ovulation, while LHβCTP and
YHR+ female mice are anovulatory due to the constant
activation of the receptor that cannot mimic the LH surge.
Contrary to the mice, excess LH action in girls may
neither be able to compensate undersupply of FSH needed
for human follicle development and progress of puberty.
Finally, the explanation may be that LHCGR expression in
human ovary does not begin until the onset of FSH
secretion at the normal age of puberty.
2.4 Potential role of gonadotropins in ovarian tumorigenesis
The potential role of gonadotropins in initiation and/or
progression of ovarian tumors has been discussed for
decades (for a recent review see [35], for example).
Intriguingly, in genetically modified animals both excess
and lack of gonadotropin action have been linked with
tumorigenesis including germ cell, sex-cord and surface
epithelial tumors. Firstly, strong stimulation of LH signal-
ling causes development of mature teratomas bilaterally in
all UBC-hCG+ females [36], while unilateral teratomas
have been detected in about 20% of FshrD580H female mice,
with some of the tumors being immature [18]. High
gonadotropin stimulation—both FSH and LH—of gran-
ulosa cells may thus interfere with oocyte maturation and
trigger parthogenetic activation of oocytes. Secondly,
LHβCTP+ females develop granulosa and theca cell
tumors with ageing, but only in a genetically predisposed
background and when the LH surge is not taking place
[31, 34, 37]. Together with the finding that such tumors do
not develop in UBC-hCG+ mice [36], it suggests that
excessive stimulation of LHCGR may be a promoting
rather than an initiating factor in this response. Constant
expression of LHβCTP also accelerates development of
the SV40 T-antigen-initiated granulosa cell tumors [38]
further implying a role for LH/hCG in ovarian sex-cord
cell tumorigenesis.
The role of FSH in promoting somatic cell tumors is
more complicated. Firstly, most Forko mice older than a
year develop both sex-cord and epithelial ovarian tumors
including granulosa cell tumors and serous papillary
epithelial adenomas [39, 40]. Aging FshrD580H+ mice
also develop ovarian surface epithelial hyperplasia [18]
and the presence of FSH accelerates the formation of
granulosa cell tumors in inhibin-α-deficient mice [24]
suggesting, that FSH signalling can both suppress and
support hyper- and metaplastic growth of several cell
types directly or indirectly. Interestingly, according to a
recent finding the expression of FSHR is promoted in
endothelial cells at the borderline area of different kinds of
human malignant tumors [41] prompting the question
about a possible role of FSH in the progression and
invasion of cancer in general.
3 Experimental animal models for gonadotropin action
in testis and male accessory glands
Similarly to ovarian function in women the gonadotropins,
particularly LH, play a key role in the differentiation and
maturation of testis in men. Mutations in LHβ and LHCGR
causes various types of pathological conditions in men
including lack of or delayed puberty, absence of secondary
sexual characteristics and arrested spermatogenesis, while
FSHβ and FSHR mutations lead to impaired testicular
function but not necessarily to infertility [7]. During the last
15 years several genetically modified animal models for
aberrant gonadotropin action have been generated and they
have greatly increased knowledge of the molecular patho-
genesis of gonadotropin-related conditions.
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3.1 Aberrations in testis and male accessory glands of LHβ
and LHCGR deficient mice
As with in females, LH action in males is essentially needed
first time during the pubertal development. The testes of
newborn LHCGR deficient, Lurko males are similar in size
and microscopic appearance to those of wild type littermates,
and their intra-abdominal location adjacent to the urinary
bladder is unchanged [5], indicating that LH signalling is not
needed for prenatal testicular development. Adult LHβ
deficient, Lhβ−/− and Lurko males instead are infertile,
with their testis weight being about 25% of that in wild-type
age-matched littermates [4–6]. The accessory glands are also
undersized consistent with decreased circulating (<10%) and
intra-testicular (<5%) testosterone levels. Testicular histolog-
ical analysis shows spermatogenesis, which is blocked at the
round spermatid stage [5, 6], and insignificant interstitium
with very few, small-sized Leydig cells [4–6]. Gene
expression analyses have confirmed an increase in the fetal
Leydig cell marker, thrombospondin-2, and reduction in
many of the steroidogenic pathway enzymes. In addition,
levels of the androgen precursor, androstenedione, are
enhanced, indicating the presence of mostly fetal and
immature Leydig cells in the Lhβ−/− testes [4].
Testosterone replacement therapy of Lurko males can
partially restore the phenotypes and improve spermatogen-
esis beyond the round spermatid stage, but the mice remain
sub-fertile. Fewer than 10% of all breedings have resulted
in pregnancy, and only two of 13 mice (15%) tested have
been fertile. The reasons for this include poor accessory sex
gland function and impaired sexual behaviour, as well as
inflammation in the epididymis and prostate in many
testosterone-treated Lurko mice [42]. Surprisingly, by the
age of 12 months the arrested spermatogenesis in untreated
Lurko testes has appeared to be progressed further, until
elongated spermatids at late stages 13–16, indicating that
spermatogenesis can be completed even without LH
signalling and high intratesticular testosterone concentra-
tion (Fig. 2). Late-onset recovery of spermatogenesis in
Lurko mice suggests that only total abolition of testicular
androgen action may result in consistent azoospermia
necessary for effective male contraception [5].
Recently, transgenic mice co-expressing binding-
deficient and signalling-deficient forms of LHCGR in
(-/-), 12 mo
(+/+), 12 mo
bar = 50 mm
a
(-/-), 2 mo
b
c d
e f
Fig. 2 Representative light
micrographs of testicular sec-
tions from homozygous Lurko
(−/−) and wild type control (+/+)
mice. Samples were taken from
Lurko (−/−) at the ages of
2 months (a and b) and
12 months (c and d) and from
control wild-type mice at
12 months (e and f). b, d, and f
are views of a, c, and e at higher
magnification. Arrows and
arrowheads indicate round
spermatids and elongated sper-
matids, respectively. mo month.
The figure is a modification
from the original figure pre-
sented in [78]
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Lurko background have been generated [43]. The male
mice demonstrate close to complete restoration of LH
action; testes of the mice descend normally to the scrotum,
are normal in weight and size, and accessory sex organs are
fully developed, all consistent with serum testosterone
concentration reset to the wild-type range. Testicular
histology also shows full spermatogenesis and normal-
sized Leydig cells. Males are fertile and sire similar
numbers of pups as wild type males. The study demon-
strates that normal LH actions can be achieved via
dimerization of binding-deficient and signalling-deficient
LHCGR in the absence of functional wild-type receptor
[43]. It will be intriguing to see whether LHCGR trans-
activation is sufficient to maintain the same complex action
of LH needed in the maintenance of female fertility.
3.2 Aberrations in male LH/hCG/YHR over-expressing
mice
Several experimental animal models demonstrate the
influence of enhanced LH signalling on the function of
testis; the stronger the LH signalling is, the more severe the
consequences are. UBC-hCGβ+ and YHR+ males are
fertile and show only mild anomalies, in agreement with
their moderate increase in bioactive hCG and LH signalling
[32, 44]. Though the mice have smaller testes than wild-
type mice, spermatogenesis is completed and quality of
sperm is normal. Similarly, the subunit Cα overproducing
males demonstrate no obvious abnormalities, in keeping
with the necessity of α/β dimerization for the biological
activity of hCG. In contrast, the double transgenic UBC-
hCG+ males expressing both α and β subunits are infertile
and their reproductive organs show severe alterations with
small testes, enlarged seminal vesicles and prostate, dilated
vasa deferentia and urinary bladder, as well as kidney
defects in adulthood due to high testosterone production
[44]. Prepubertal UBC-hCG+ males have large Leydig cell
nodules, classified as adenomas that reach their maximum
size at the age of 10 days and that regress between the ages
of 21 and 60 days [45]. The expression pattern of fetal and
adult Leydig cell markers indicates that the adenomas in the
UBC-hCG+ males are derived from fetal Leydig cells, and
these adenomatous fetal Leydig cells regress according to
their normal lifespan, explaining the disappearance and
absence of Leydig cell adenomas in adult age [45].
Moreover, the adult Leydig cells appear to be resistant to
hCG/LH-stimulated formation of adenomas. Surprisingly,
neither YHR+ or UBC-hCG+ males show any signs of
precocious puberty despite prematurely increased circulat-
ing testosterone [32, 45]. This suggests that the onset of
pubertal maturation in mice is already at its minimum in
wild-type males, or that it is triggered by some other
unknown factor.
3.3 Aberrations in testis and male accessory glands
in FSHβ and FSHR deficient mice
FSH signalling is not as crucial for testicular function as LH
is. Both FSHβ and FSHR deficient (Fshβ−/− and Forko)
mice are fertile despite the reduced testis size and
seminiferous tubule volume [1–3]. Stereological analyses
have confirmed around 30% reduction in Sertoli cell
number and germ cell carrying capacity, consistent with
reduced testis size in Fshβ−/− mice [46, 47]. The number
of Leydig cells and concentration of intratesticular testos-
terone increase slowly in Forko mice after puberty and are
significantly reduced in adult animals [48]. This is
associated with reduced levels of mRNA encoding P450-
scc, 3ß-hydroxysteroid dehydrogenase type VI, and StAR
in Forko mice [48]. The accessory glands of the Fshβ−/−
mice are however normal, verifying the presence of
adequate number of Leydig cells and serum testosterone
concentration [1].
Spermatogenesis is completed and many tubules contain
mature spermatozoa in Fshβ−/− and Forko testes though
partial spermatogenic failure has been observed [1–3]. Flow
cytometric evaluation of germ cells has revealed a
significant increase in the percentage of spermatogonial
and non-germ cells in Forko mice, with substantially less
elongated spermatids than their wild-type littermates.
Defects in sperm head shape, chromatin condensation, and
chromatin remodelling are also apparent [49, 50], thus
leading to decreased sperm viability and motility, and
consequently reduced fertility and a delay in the first
mating [49].
3.4 Aberrations in male FSH over-expressing mice
Overexpression of FSH, such as in Mt1-hFSH+ mice,
results in normal testicular development and lack of any
obvious histological defects in adult testes [24]. The
seminiferous tubules are healthy and intact, spermatozoa
are abundant in the lumen, and the number of Leydig cells
in the interstitial spaces is normal [24]. In addition, Mt1-
FSH+ mice show enlarged seminal vesicles secondary to
elevated serum testosterone levels. Nevertheless, the Mt1-
FSH+ mice are infertile that is thus caused by behavioural
rather than structural defects. In other mouse lines with
enhanced FSH signalling, obvious perturbations in testicu-
lar function have not been reported.
Interestingly, the testes of Ins2-FSH+xhpg mice (for
details, see Table 1) are up to 5-fold larger than those of
hpg only mice depending on FSH concentration. Only the
Ins2-FSH+xhpg males having serum FSH level higher than
1 IU/liter show larger testes than hpg-only mice, indicating
a physiological FSH threshold for the testicular response
[51, 52]. Enlarged Ins2-FSH+xhpg testes contain round
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spermatids and a sparse number of elongated spermatids.
Hence without LH-induced testosterone production, FSH
action alone on Sertoli cells may facilitate the completion
of meiosis and minimal initiation, but not completion of
spermiogenesis. Furthermore, transgenic FSH expression in
hpg mice restores the number of Sertoli cells to the same
level as in mature wild-type mice in a dose-dependent
fashion, despite the absence of LH and persistently low
intratesticular testosterone [52]. Altogether, FSH alone can
stimulate the complete development of Sertoli cells but
spermatogenesis does not occur without LH signalling [52].
4 Consequences of excessive gonadotropin action
on pituitary function
The aberrant action of gonadotropins leads to many
endocrine disorders, both in humans and experimental
animal models [7, 53]. The intensity and complexity of
the pathology are affected by the amount of hormones
produced, duration of the stimulus, and the period in which
the hormone stimulus is active. Transgenic mice with
overproduction of hCG/LH, such as LHβCTP+,UBC-
hCGβ+ and UBC-hCG+ mice have revealed novel pheno-
types in pituitary function, both in males and females [31,
33, 36, 44, 54–56]. Female mice bearing constitutively
active mutations of the FSHR, FshrD580H+ mice, also
demonstrate distinct alterations in their pituitary function
[18]. However, in all of the mouse strains the pituitary
disorders are apparently secondary to increased gonadal
hormone production.
The UBC-hCGβ+ mice produce moderate amounts of
hCGβ subunit in a large number of tissues [33, 44], and the
transgenic hCGβ-subunit associates with the endogenously
expressed common α-subunit to form bioactive hCG. The
dimerization results in around 40-fold increase in LH/hCG
bioactivity in females [33], but only 3- to 4-fold increase in
males [44]. The amount of endogenous α-subunit limits the
dimerization process of hCG that is obligatory for hormonal
activity, the individual hCG subunits being devoid of
bioactivity [57]. The difference between male and female
hCG secretion may be due to differences in feedback
regulation of the common α-subunit expression by gonadal
hormones [58]. Accordingly, UBC-hCGβ+ females produce
high amounts of estradiol, testosterone and progesterone
from the early stages of sexual maturation [33].
One of the most intriguing phenotypes observed in the
UBC-hCGβ+ mice is the presence of lactotrope hyperplasia
followed by development of prolactinomas in adult female
mice [33, 55]. This is strictly dependent on the ovarian
function, since ovariectomy prevents the hyperprolactinemia
and pituitary adenoma formation, despite persistently elevat-
ed serum hCG concentration. Similarly, the FshrD580H+
females exhibit increased serum concentration of estradiol
and prolactin in association with adenomatous pituitary
growth [18]. The constantly enhanced estradiol stimulation
apparently causes the development of prolactinomas in
FshrD580H+females [18], whereas in UBC-hCGβ+ mice
ovarian estradiol production is elevated only temporarily
before puberty [44]. The well-known influence of estradiol in
the induction of pituitary adenomas [59] is therefore
insufficient to explain the tumor pathogenesis in the latter
mice. Instead, ovarian progesterone production remains high
in UBC-hCGβ+females and in agreement with this, excess
progesterone has been shown to promote the growth of
primary mouse pituitary cells and rat somatolactotrope GH3
cells in the presence of physiological levels of estradiol [55].
Evidence for the involvement of progesterone is also
obtained in vivo; antiprogestin mifepristone treatment inhibits
pituitary tumor growth in UBC-hCGβ+ females, and
combined estradiol/progesterone treatment is more effective
than estrogen treatment alone in inducing tumor growth after
gonadectomy. The molecular mechanism of progestin-
induced growth of rodent pituitary cells involves the
activation of the tumorigenic cyclin D1/cyclin-dependent
kinase 4/retinoblastoma protein/transcription factor E2F1
signaling cascade [55], which has profound similarities with
development of human pituitary adenomas [60]. The
importance of these studies lies in the potential role of the
hCG overproducing mouse model for addressing the devel-
opment and treatment of pituitary adenomas in individuals
with high gonadotropin levels (such as after menopause).
The double transgenic UBC-hCG+ mouse model that co-
expresses both the common α- and hCGβ-subunit trans-
genes produces highly elevated levels of dimeric hCG,
reaching as high as 2000-fold increase in LH/hCG biological
activity [36, 44]. In UBC-hCG+ males the concentration of
androgens is elevated from the early development and they
induce a profound and persistent malfunction of the
neuroendocrine feedback control [56]. This results in
accelerated hypothalamic GnRH pulse release and concom-
itant suppression of the pituitary-gonadal axis, which can be
re-established only by blocking the androgen action perina-
tally [56]. These findings suggest the existence of a critical
window in perinatal life, when androgens determine the level
of activation of the male hypothalamic-pituitary axis, and
that high androgen concentration can persistently shut down
the pituitary gonadotrope differentiation and gonadotropin
synthesis and secretion. A direct testosterone-dependent
stimulation of the hypothalamic aromatase expression has
been demonstrated in UBC-hCG+ males, and hence hypo-
thalamic aromatization of gonad-derived androgens to
estradiol may play a key role. These findings strongly
suggest that androgen excess is able to disrupt the
developmental programming of the male hypothalamic-
pituitary-gonadal axis in mice [56].
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5 Impact of abnormal gonadotropin action on tissues
outside the hypothalamic-pituitary-gonadal-axis
Gonadotropins, in particular LH, are suggested to exert their
effect via receptor binding on several extra-gonadal tissues. In
addition, imbalanced gonadal hormone production caused by
disturbed gonadotropin action affects the function of several
tissues outside the hypothalamic-pituitary-gonadal axis. The
mammary gland is an obvious target for the enhanced
hormone action. Increased LH and FSH signalling may
indeed cause hyperplastic or even malignant growth of the
gland directly or due to the enhanced ovarian estradiol,
prolactin and/or progesterone production. FshrD580H+
females display typical pseudopregnant appearance with
augmented lobulo-alveolar growth, but malignant transfor-
mation has not been detected in this strain [18]. Mammary
gland development is also accelerated in LHβCTP+ mice,
with young virgin mice having glands typical of late
pregnancy [61]. During chronic LH signalling, mammary
gland hyperplasia advances spontaneously to tumors, mainly
in the form of intraepithelial neoplasias. They can further
progress to invasive carcinomas, if the mice are treated with
the mammary gland carcinogen, 7,12-dimethylbenz(a)antr-
harcene [37, 61]. The aging UBC-hCGβ+ females show
mammary epithelial hyperplasia and cytoplasm vacuolization
that advances to adenocarcinoma with papillary or non-
differentiated pattern [33]. The tumors are estrogen and
progesterone receptor-negative, but instead resemble those
induced by activated wnt/β-catenin pathway. Accordingly,
they show increased β-catenin stabilization via up-regulation
of wnt5b and wnt7b that is independent of the changes in
ovarian steroidogenesis [62]. The capability of LH/hCG to
modulate directly the wnt/β-catenin pathway in mammary
epithelial cells may explain the severity of the consequences
of its chronic and elevated action compared to FSH, the
receptor of which is not expressed in the mammary gland.
During a woman’s reproductive years, FSH has well-
established osteoprotective functions via enhanced estrogen
production. In agreement with this, the ageing Forko females
have skeletal abnormalities including kyphosis [23]. Con-
versely, in the presence of estrogen, FSH has been indicated
to decrease bone mass directly via FSHR in osteoclasts [63].
That is supported by some clinical studies [64] and increased
bone mass and decreased osteoclastic resorption in haploin-
sufficient FSHβ+/− mice in comparison to FSHβ+/+ mice
[63]. The bone metabolism in Ins2-hFSH+ and Ins2-hFSH
+xhpg mice however demonstrate that FSH has, at least in
mice, primarily anabolic effect on bone and that this effect is
ovary-dependent and does not involve direct FSH actions on
bone, or LH signalling either [65].
Abnormal gonadotropin function can lead to two different
types of aberrations in adrenal glands. Firstly, gonadectomy
and the concomitant increase in LH trigger adrenal hyperplasia
and tumorigenesis in certain inbred mouse strains [66]. This is
followed by increased proliferation of non-steroidogenic small
spindle-shaped ‘A cells’ in the subcapsular adrenal cortex,
and later on, by appearance of LH-responsive steroidogenic B
cells that together construct disorganized tumorigenic adreno-
cortical architecture [66]. Ectopic upregulation of adrenal
LHCGR, however, occurs in both tumorigenic and non-
tumorigenic strains of mice, their F2 crossbreeds and their
backcrosses, thus implying that adrenal LH action is not the
immediate cause of tumors, but rather a promoting factor. A
linkage analysis has revealed that post-gonadectomy adrenal
tumorigenesis is driven by a quantitative trait locus on
chromosome 18 and modulated by another one on chromo-
some 8, neither of them harbouring Lhcgr [66]. Other types of
histological changes are observed in the adrenal gland of
female LHβCTP+ [67], UBC-hCGβ+ [33] and FshrD580H+
[18] mice. At the cortico-medullary junction, a distinct layer
of foamy and multinuclear cells is seen, which resembles the
layer existing in estrogen-rich UBC-Arom+ male mice and the
layer induced by chronic estrogen administration [68]. The
estrogen-induced hyperplasia is accompanied by enhanced
corticosterone synthesis and development of Cushing’s
syndrome in the LHβCTP+ mice [67].
An interesting hypothesis is that LH can increase the
susceptibility to Alzheimer disease (AD) [69]. Circumstan-
tial evidence includes the presence of LHCGR in several
brain regions [70, 71], the ability of LH and hCG to cross
the blood-brain barrier [71], elevated LH concentrations in
AD sufferers [72, 73], the linkage of certain LHCGR
variants with reduced risk of AD [74], and the ability of LH
to alter amyloid precursor processing toward the amyloido-
genic pathway in vitro [75]. The cross-breedings of Lhcgr
knockout mice and APPsw+ Alzheimer model mice
expressing human amyloid precursor, convincingly support
this hypothesis; in the absence of LH action, accumulation
of amyloid-β peptide (Aβ) is reduced, astrogliosis eases,
and the production of several neuroproteins is corrected
[76]. Elevated LH levels may hence promote Aβ accumu-
lation and hasten AD progression and the cross-breedings
of the two mouse strains may turn out to be useful when
investigating AD pathogenesis. In addition, the abolition of
FSH signalling leads to neurodegenerative changes due to
the depletion of circulating estrogen. Forko females
demonstrate several biochemical and morphological alter-
ations in central and peripheral neurons [77].
6 Conclusions
Numerous abnormalities in the animal models with disrupted
or enhanced gonadotropin action demonstrate the highly
sensitive nature of the reproductive systems. Small changes
in the circulatory gonadotropin concentration and timing of
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gonadotropin action may alter the functions of gonads, the
ovary in particular, and more drastic alterations like the
complete abolition of gonadotropin action or chronic and
intensely enhanced action, leads to sub- or infertility. In
humans, deficiency of gonadotropins or their receptors results
in hypogonadotropic and hypergonadotropic hypogonadism,
respectively, while constitutively active gonadotropin recep-
tors and gonadotropin-producing pituitary tumors can cause
enhanced and chronic gonadotropin stimulus. Gonadotropin
levels are also raised notably during pregnancy and postmen-
opausal years exposing women for enhanced gonadotropin
stimulus. Thus mouse models are able to elucidate the
mechanisms between the initial genetic defect and the
eventual phenotype and may also predict possible outcomes
of similar defects in humans paving the way for improved
diagnostic and therapeutic strategies for these conditions.
For female fertility it is crucial to maintain the primordial
follicular pool and ensure a proper follicular development and
ovulation. The gain-of-function mouse lines demonstrate how
a modest increase in FSH action can enhance fertility, but how
more excessive and chronic gonadotropin action, of both FSH
and LH, leads to accelerated loss of the primordial follicles,
improper follicle development, enhanced ovarian hormone
production, anovulation, and finally to disruption of the
function of the hypothalamic-pituitary-gonadal axis. For
males in turn it is fundamental to ensure proper development
and function of the Leydig and Sertoli cells and to maintain
undisrupted spermatogenesis, which functions are sensitive to
lack of and excessive gonadotropin, mainly LH action.
The animal models have also proven valuable in the
exploration of gonadotropin dependent biological systems
outside of the gonads. They include developmental program-
ming of the male hypothalamic-pituitary axis in mice and the
linkage of the wnt/β-catenin and LH pathways in the
development of mammary carcinomas. There is a strong
correlation between the intensity of chronic gonadotropin
signalling and severity of the outcome. Therefore a varieties of
models are needed to phenocopy and predict corresponding
human syndromes. Although some of themouse lines produce
supra-physiological levels of gonadotropins, these may
demonstrate the amplified effects of the consequences of
long-lasting chronic gonadotropin stimulation.
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